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Background
Chronic hydrocephalus (hydrocephalus) is characterised
by impaired gait, and associated with decreased cerebral
blood flow and oxygen delivery. We investigated the role
of chronic hypoxia in the caudate which is a known motor
nucleus involved in gait control. Also, increased ICP and
vascular compression as the result of enlarged ventricles
may be directly responsible for the gait problems in
hydrocephalus. VEGF, which is triggered by ischemic/
hypoxic events causes associated adaptive angiogenesis
and also plays a critical role in neuronal protection. Previ-
ously, using an experimental model of hydrocephalus, we
have shown decreased cerebral blood flow, oxygen deliv-
ery and increased capillary density. Here we investigated
whether neuronal and glial VEGF-R2 expression is associ-
ated with an adaptive angiogenesis in the caudate.
Materials and methods
We investigated the relationship between the duration
and severity of hydrocephalus and the percentage expres-
sion of VEGFR2+ neurons, glia and blood vessels (BV) in
the periventricular and deep layers of the caudate. Hydro-
cephalic animals were divided into Short Term (ST, n = 5)
and Long Term (LT, n = 5) and compared with Surgical
Controls (SC, n = 5). The density of blood vessels and cel-
lular VEGF-R2+ was estimated using stereological cell
counting methods. Values were expressed as %VEGF-R2 +
cells to the total number of cells in each region.
Results
Overall, there was approximately 300–400% increase in
%VEGF-R2+ neurons, and approximately 10–15%
increase in %VEGFR-R2 glia in the caudate of hydro-
cephalic animals compared to SC. Specifically, %VEGFR-
R2+ neurons were significantly greater in LT (55–60%)
than SC (10–25%). Similarly, %VEGF-R2+ glia were sig-
nificantly higher in hydrocephalic animals (55–60%),
then SC (15–25%). BV density was found to decrease in
hydrocephalic animals than SC. Overall, we found that
the BV density decreased 60% in the periventricular cau-
date and 20% in the deep caudate compared to SC. BV
density was not significantly correlated with ICP or CSF
ventricular volume. Finally, caudate volume was not sig-
nificantly different in hydrocephalic animals compared to
SC.
Conclusion
The 300–400% increase in %VEGF-R2+ neurons and glia
in hydrocephalus indicates a stimulated VEGF response
that may be related to hypoxia in the caudate. The
observed increase in VEGF-R2+ was not associated with
angiogenesis, however may play a role in neuroprotec-
tion. Modulation of VEGF receptors may be important in
our understanding of the role of hypoxic in the patho-
physiology of hydrocephalus and lead to adjunct treat-
ments.
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